1. Inicio
  2. Publicaciones
  3. Peripheral blood stem cells versus bone marrow graft for non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Peripheral blood stem cells versus bone marrow graft for non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Nagler A.
  • Swoboda R.
  • Ferhat A.-T.
  • Blaise D.
  • Koc M.
  • Raiola A.M.
  • Busca A.
  • Pavlu J.
  • Bramanti S.
  • Itälä-Remes M.
  • Colorado M.
  • Vydra J.
  • Kulagin A.
  • Bazarbachi A.
  • Mohty M.
  • Ciceri F.

Grupos

Abstract

Haploidentical stem cell transplantation (haplo-HSCT) with post-transplant cyclophosphamide (PTCy) is a therapeutic option for secondary acute myeloid leukemia (sAML). The study aimed to compare peripheral blood stem cells (PBSC) vs. bone marrow (BM) as a graft source for haplo-HSCT with PTCy in patients with sAML in first complete remission. A total of 554 patients were included, BM = 136, PBSC = 418. Median follow-up was 3 years. The median year of transplant was 2018 (range, 2010–2021). The antecedent hematological disease was myelodysplastic syndrome /myeloproliferative neoplasms in most patients. Patients in the BM group were younger, median age 59.2 vs. 61.7 years (p = 0.008), and received myeloablative conditioning more frequently (66.4% vs. 47.4%, p < 0.001). Time from diagnosis to haplo-HSCT was 5.3 vs. 4.8 months, respectively (p = 0.019). Performance status, cytogenetic risk, gender, cytomegalovirus serostatus, and donor age did not differ. There were no differences between the groups with respect to main transplantation outcomes. In conclusion, outcomes of haplo-HSCT with PTCy in sAML with either PBSC or BM grafts are similar, with no differences in major transplantation outcomes. © The Author(s) 2026.

Datos de la publicación

ISSN/ISSNe:
0268-3369, 1476-5365

BONE MARROW TRANSPLANTATION  SPRINGERNATURE

Tipo:
Article
Páginas:
559-568
PubMed:
41882108
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,998 SCImago ℠
Cuartil:
Q2 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Adult; Aged; Bone Marrow Transplantation; Cyclophosphamide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Conditioning; Transplantation, Haploidentical; cyclophosphamide; cyclosporine; mycophenolate mofetil; tacrolimus; cyclophosphamide; Acute Leukemia Working Party; adult; aged; Article; bone marrow transplantation; cause of death; European Society for Blood and Marrow Transplantation; female; haploidentical transplantation; health care organization; hematopoietic stem cell transplantation; human; immunosuppressive treatment; incidence; infection; major clinical study; male; non T depleted haploidentical transplantation; overall survival; peripheral blood stem cell; prophylaxis; recurrence free survival; remission; secondary acute myeloid leukemia; survival analysis; acute myeloid leukemia; middle aged; mortality; peripheral blood stem cell transplantation; procedures; remission; therapy; t

Cita

Compartir